ClinicalTrials.gg
Not yet recruitingNCT07430059SLIM-1Updated Jun 30, 2026

Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

A Phase 1 interventional study of Semaglutide Implant (NPM-139) and Semaglutide (Wegovy) weekly injection in Obesity & Overweight, sponsored by Vivani Medical, Inc. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Vivani Medical, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.

Planned enrollment
133rd of 143
20 · median 100
Started
2026
with 29 others
Phase 1
19 of 143
9 open now
Primary completion
2026-12
later than 20 of 76 live
Registered
116th of 143
by date

Among the 143 studies testing semaglutide in Obesity, this one is the 133rd largest by planned enrollment, is one of 30 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 20 of the 76 other live ones, and was the 116th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies testing semaglutide in Obesity, or all of them as a file.
02

Study summary

The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants who are otherwise healthy..

Read the detailed description

This open label, randomized, parallel-group study will evaluate participants with a body mass index (BMI) between 27 and 40 kg/m2 (inclusive). Safety, tolerability and PK data will be collected and evaluated for the 4-week treatment period. Participants will undergo a Screening Visit and those who meet eligibility will be randomized (1:1) to one of 2 study groups:

  • Group 1: Semaglutide Implant (NPM-139)
  • Group 2: Semaglutide 0.25 mg SC once weekly All participants will be domiciled for at least 48 hours following insertion of the implant (Group 1) or first dose of semaglutide 0.25 mg (Group 2).

Subsequently, participants will return to the clinic weekly until study end. At each of these visits, participants will have blood samples drawn for PK. After sample collections, site staff will administer semaglutide injections to participants in Group 2.

After 4 weeks of treatment (end of study), final PK samples will be collected and participants with implants will undergo a brief implant removal procedure under local anesthetic.

03

Conditions studied

  • Obesity & Overweight

Keywords

  • obesity
  • overweight
  • semaglutide
  • implant
  • glp-1
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 27 and 40 kg/m2 (inclusive)
  • \</= 6.0% and FPG \</+ 6.7 mmil/L
  • >/= 60 mL/m2
  • No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination

Exclusion criteria

Exclusion Criteria:

  • Type 1 or Type 2 Diabetesa
  • A medical condition that could potentially affect study participation and/or personal well-being, as judged by the Investigator
  • Treatment with glucose lowering agent(s) within 3 months before Screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Semaglutide Implant (NPM-139)

    Each participants in this arm will receive one Semaglutide Implant (NPM-139) which will be inserted subcutaneously in the upper outer arm and subsequently removed after 4 weeks of treatment.

    Combination Product: Semaglutide Implant (NPM-139)

  • Active comparator
    Semaglutide (Wegovy) weekly injection

    Each participant in this arm will receive Semaglutide (Wegovy) 0.25 mg subcutaneous injection weekly for 4 weeks of treatment.

    Drug: Semaglutide (Wegovy) weekly injection

Interventions

  • Semaglutide Implant (NPM-139) is a drug/device combination product consisting of a subdermal titanium implant \~23 mm long and 2 mm in diameter, containing a sterile liquid formulation of semaglutide that is released from the implant at a substantially constant rate over at least 15 weeks.

  • Semaglutide (Wegovy) is a clear, colorless solution provided as Wegovy FlexTouch four-dose pens: 0.25 mg/0.5 mL. It is injected SC in the abdomen, thigh or upper arm once/week.

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC)

    total semaglutide concentration

    Time frame: 4 weeks

  2. Maximum plasma concentration (Cmax)

    Maximal semaglutide concentration

    Time frame: 4 weeks

  3. Time to maximum semaglutide concentration (Tmax)

    Time to reach maximal semaglutide concentration

    Time frame: 4 weeks

  4. Adverse Events

    Incidence of treatment-emergent adverse events

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 5 months is below that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 24, 2026
StartEst.
Jul 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07430059
Lead sponsor
Vivani Medical, Inc
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Chief Medical Officer, MD
Contact
clinical@vivanai.com
4155068462
Lisa Porter, MD
study director · Vivani Medical, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion